Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Thoracic 2Gastrointestinal 2Sarcoma 1Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Sezary Syndrome 1Sarcoma, Synovial 1Mycosis Fungoides 1Liposarcoma, Myxoid 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Interferon-gamma × Sarcoma × Clear all
NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 15 charts
LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡